Coloplast A/S (CLPBF)
USD 112.54
(0.0%)
USD 112.54
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 19.56 Billion DKK | 4.59% |
| 2022 | 18.7 Billion DKK | 571.5% |
| 2021 | 2.78 Billion DKK | 59.47% |
| 2020 | 1.74 Billion DKK | 44.62% |
| 2019 | 1.2 Billion DKK | -11.24% |
| 2018 | 1.36 Billion DKK | -6.52% |
| 2017 | 1.45 Billion DKK | 555.86% |
| 2016 | 222 Million DKK | 122.0% |
| 2015 | 100 Million DKK | 8.7% |
| 2014 | 92 Million DKK | -17.12% |
| 2013 | 111 Million DKK | -91.44% |
| 2012 | 1.29 Billion DKK | -38.11% |
| 2011 | 2.09 Billion DKK | 1117.44% |
| 2010 | 172 Million DKK | -93.09% |
| 2009 | 2.48 Billion DKK | -23.88% |
| 2008 | 3.27 Billion DKK | 5.59% |
| 2007 | 3.09 Billion DKK | 3.58% |
| 2006 | 2.99 Billion DKK | 66.3% |
| 2005 | 1.79 Billion DKK | 0.0% |
| 2004 | - DKK | -100.0% |
| 2003 | 2.3 Billion DKK | 28.48% |
| 2002 | 1.79 Billion DKK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 24.5 Billion DKK | 13.31% |
| 2024 Q1 | 21.63 Billion DKK | 10.54% |
| 2024 Q3 | 19.52 Billion DKK | -20.34% |
| 2023 Q3 | 22.11 Billion DKK | 2.16% |
| 2023 Q1 | 22.19 Billion DKK | 18.63% |
| 2023 FY | 19.56 Billion DKK | 4.59% |
| 2023 Q4 | 19.56 Billion DKK | -11.52% |
| 2023 Q2 | 21.64 Billion DKK | -2.46% |
| 2022 Q2 | 21.08 Billion DKK | 318.67% |
| 2022 Q1 | 5.03 Billion DKK | 80.76% |
| 2022 FY | 18.7 Billion DKK | 571.5% |
| 2022 Q3 | 20.59 Billion DKK | -2.32% |
| 2022 Q4 | 18.7 Billion DKK | -9.16% |
| 2021 Q1 | 4.66 Billion DKK | 167.03% |
| 2021 FY | 2.78 Billion DKK | 59.47% |
| 2021 Q4 | 2.78 Billion DKK | -34.92% |
| 2021 Q3 | 4.28 Billion DKK | 3.78% |
| 2021 Q2 | 4.12 Billion DKK | -11.58% |
| 2020 Q4 | 1.74 Billion DKK | -42.74% |
| 2020 Q1 | 3.57 Billion DKK | 195.86% |
| 2020 Q2 | 3.16 Billion DKK | -11.33% |
| 2020 Q3 | 3.05 Billion DKK | -3.72% |
| 2020 FY | 1.74 Billion DKK | 44.62% |
| 2019 Q1 | 3.13 Billion DKK | 130.49% |
| 2019 FY | 1.2 Billion DKK | -11.24% |
| 2019 Q3 | 2.93 Billion DKK | 9.4% |
| 2019 Q4 | 1.2 Billion DKK | -58.8% |
| 2019 Q2 | 2.68 Billion DKK | -14.57% |
| 2018 Q3 | 3.07 Billion DKK | -6.46% |
| 2018 Q1 | 2.89 Billion DKK | 98.83% |
| 2018 Q4 | 1.36 Billion DKK | -55.7% |
| 2018 Q2 | 3.28 Billion DKK | 13.44% |
| 2018 FY | 1.36 Billion DKK | -6.52% |
| 2017 Q3 | 2.54 Billion DKK | -4.32% |
| 2017 Q2 | 2.66 Billion DKK | -7.57% |
| 2017 Q1 | 2.88 Billion DKK | 1197.3% |
| 2017 Q4 | 1.45 Billion DKK | -42.83% |
| 2017 FY | 1.45 Billion DKK | 555.86% |
| 2016 Q4 | 222 Million DKK | -75.95% |
| 2016 Q2 | 25 Million DKK | -93.61% |
| 2016 FY | 222 Million DKK | 122.0% |
| 2016 Q3 | 923 Million DKK | 3592.0% |
| 2016 Q1 | 391 Million DKK | 291.0% |
| 2015 FY | 100 Million DKK | 8.7% |
| 2015 Q2 | 467 Million DKK | 27.25% |
| 2015 Q1 | 367 Million DKK | 298.91% |
| 2015 Q3 | 779 Million DKK | 66.81% |
| 2015 Q4 | 100 Million DKK | -87.16% |
| 2014 Q2 | 130 Million DKK | 0.78% |
| 2014 Q4 | 92 Million DKK | -40.26% |
| 2014 FY | 92 Million DKK | -17.12% |
| 2014 Q1 | 129 Million DKK | 16.22% |
| 2014 Q3 | 154 Million DKK | 18.46% |
| 2013 Q3 | 146 Million DKK | -88.86% |
| 2013 FY | 111 Million DKK | -91.44% |
| 2013 Q4 | 111 Million DKK | -23.97% |
| 2013 Q2 | 1.31 Billion DKK | -1.8% |
| 2013 Q1 | 1.33 Billion DKK | 3.01% |
| 2012 Q3 | 2.13 Billion DKK | 12.13% |
| 2012 Q4 | 1.29 Billion DKK | -39.3% |
| 2012 FY | 1.29 Billion DKK | -38.11% |
| 2012 Q1 | 2.09 Billion DKK | 0.0% |
| 2012 Q2 | 1.9 Billion DKK | -9.07% |
| 2011 Q3 | 2.04 Billion DKK | -3.54% |
| 2011 FY | 2.09 Billion DKK | 1117.44% |
| 2011 Q1 | 2.22 Billion DKK | 1195.93% |
| 2011 Q2 | 2.11 Billion DKK | -4.93% |
| 2011 Q4 | 2.09 Billion DKK | 2.45% |
| 2010 Q3 | 2.23 Billion DKK | 2.01% |
| 2010 Q4 | 172 Million DKK | -92.31% |
| 2010 FY | 172 Million DKK | -93.09% |
| 2010 Q2 | 2.19 Billion DKK | -3.65% |
| 2010 Q1 | 2.27 Billion DKK | -8.56% |
| 2009 FY | 2.48 Billion DKK | -23.88% |
| 2009 Q4 | 2.48 Billion DKK | 0.0% |
| 2008 FY | 3.27 Billion DKK | 5.59% |
| 2007 FY | 3.09 Billion DKK | 3.58% |
| 2006 FY | 2.99 Billion DKK | 66.3% |
| 2005 FY | 1.79 Billion DKK | 0.0% |
| 2004 FY | - DKK | -100.0% |
| 2003 FY | 2.3 Billion DKK | 28.48% |
| 2002 FY | 1.79 Billion DKK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 500 Thousand USD | -3913300.0% |
| Ansell Limited | 855.59 Million USD | -2186.945% |
| Ansell Limited | 857.2 Million USD | -2182.664% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 22.41 Million USD | -87207.61% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 20.93 Thousand USD | -93465388.417% |
| Psykey, Inc. | 1.01 Million USD | -1936076.529% |
| ConvaTec Group Plc | 1.31 Billion USD | -1393.041% |
| ConvaTec Group Plc | 1.31 Billion USD | -1390.933% |
| Encision Inc. | 1.33 Million USD | -1467569.565% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | -847427.003% |
| Innovative MedTech Inc. | 1.87 Million USD | -1041681.469% |
| LifePoint, Inc. | 446.74 Thousand USD | -4379852.545% |
| Medite Cancer Diagnostics, Inc. | 5.39 Million USD | -362642.673% |
| Paradigm Medical Industries, Inc. | 2.18 Million USD | -893778.483% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | - USD | -Infinity% |
| Reflect Scientific, Inc. | 242.64 Thousand USD | -8063977.414% |
| SmileDirectClub, Inc. | 871.79 Million USD | -2144.445% |
| Sector 10, Inc. | 164 Thousand USD | -11930997.561% |
| Shandong Weigao Group Medical Polymer Company Limited | 674.01 Million USD | -2803.065% |
| SheerVision, Inc. | 75 Thousand USD | -26089233.333% |
| United Health Products, Inc. | 755.98 Thousand USD | -2588165.173% |
| Vasamed, Inc. | 23.45 Thousand USD | -83441264.606% |
| Wearable Health Solutions, Inc. | 2.76 Million USD | -706961.217% |
| Yubo International Biotech Limited | 790.49 Thousand USD | -2475171.948% |